Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Ophthalmology · Antimalarial Toxic Maculopathy

Taking Action: Treatment and Managing Your Care Transition

At a Glance

The main treatment for antimalarial toxic maculopathy is medically supervised stopping of hydroxychloroquine or chloroquine; established retinal damage cannot be reversed with surgery or vitamins. A rheumatologist should choose an alternative and eye doctors should monitor for worsening after stopping.

Finding out that a medication you rely on is damaging your eyes is difficult news. Because there is currently no medical “cure,” surgery, or vitamin that can reverse antimalarial toxic maculopathy, the primary treatment is to discontinue the medication [1][2].

Do not change or stop your medication on your own. Abruptly discontinuing based on an early screening report or reading this guide carries a high risk of causing a severe flare of your underlying disease.

However, stopping these drugs is not as simple as just putting the bottle away. Because hydroxychloroquine and chloroquine are often “anchor” treatments for conditions like lupus and rheumatoid arthritis, stopping them requires a carefully coordinated handoff between your eye doctor and your rheumatologist.

Why Stopping Must Be Coordinated

The ophthalmologist’s role is to diagnose the toxicity and determine its severity. However, they generally do not manage your lupus or arthritis. The decision of how and when to switch medications must be led by your rheumatologist or dermatologist [3].

Stopping these medications abruptly without a backup plan carries a high risk of a flare (a sudden worsening of your underlying disease) [4]. In one study of patients with lupus whose disease was in remission, withdrawal of hydroxychloroquine due to eye toxicity resulted in flares for about 31% within three years, compared to only 12% of those who stayed on the drug [4]. These flares can be severe and may affect other organs, like the kidneys [4][5].

Finding a Safe Alternative

Your rheumatologist will work to find a new “disease-modifying” treatment that does not carry the same risk to your retinas. Depending on your specific condition, pregnancy plans, and organ involvement, they may consider several alternatives. There is no universal substitute:

  • For Lupus: Medications like methotrexate, azathioprine, or mycophenolate mofetil are often used [5]. In some cases, newer “biologic” therapies like belimumab may be added to help control the disease [6][7].
  • For Rheumatoid Arthritis: Methotrexate is a common alternative, or your doctor may suggest leflunomide or other biologic agents [8][9].

During this transition, your doctor may use a short course of glucocorticoids (steroids) to “bridge” the gap and keep your symptoms under control while the new medication takes effect [5][10]. Note that steroid bridging is an option with its own significant long-term risks, not a guaranteed step.

Transition Checklist:

  • Ensure the ophthalmologist has sent the findings directly to the prescribing rheumatologist.
  • Schedule a prompt appointment with the rheumatologist to discuss replacement therapy.
  • Ask what specific symptoms of a lupus/arthritis flare you should watch for.

What to Expect After Stopping

It is important to have realistic expectations for your vision after the medication is discontinued.

  • The “Washout” Period: These drugs stay in your body’s tissues for a very long time—sometimes months or even years [11].
  • Continued Progression: Because the drug clears slowly, the damage to your retina can continue to worsen for a period of time after your last dose [12]. This is especially true if the toxicity was caught in an advanced stage [13][14].
  • Long-Term Monitoring: You will likely need to continue regular eye exams for several years after stopping the medication to ensure the retina has stabilized [11][15].

A Note on Supplements

While you may see advertisements for eye vitamins like lutein or zeaxanthin, there is currently no clinical evidence that these supplements can treat or prevent antimalarial toxicity in humans [16][1]. Always talk to your doctors before adding any supplements to your routine, as they are not a substitute for stopping the offending medication.

Common questions in this guide

Should I stop hydroxychloroquine or chloroquine as soon as eye toxicity is suspected?
Do not stop either medicine on your own. The ophthalmologist should communicate the findings to the prescribing clinician, and the rheumatologist or dermatologist should coordinate when and how to change treatment because abrupt withdrawal can trigger a flare of the underlying disease.
Will my retinal damage improve immediately after I stop the antimalarial medicine?
Stopping the medicine removes further exposure but does not reverse established retinal damage. Hydroxychloroquine and chloroquine can remain in body tissues for months or years, so retinal changes may continue or worsen for a time before stabilizing, especially when toxicity was advanced.
What can replace hydroxychloroquine if I have lupus or rheumatoid arthritis?
There is no single replacement for everyone. Depending on your disease, pregnancy plans, and organ involvement, your rheumatologist may consider medicines such as methotrexate, azathioprine, mycophenolate mofetil, leflunomide, or a biologic treatment. A short steroid course may sometimes bridge the transition.
How long will I need eye exams after stopping hydroxychloroquine or chloroquine?
You may need regular eye examinations for several years after stopping. These visits help your eye doctor check whether the retina has stabilized and identify delayed progression while the medicine slowly leaves body tissues.
Can lutein or zeaxanthin supplements treat antimalarial toxic maculopathy?
There is no clinical evidence that lutein or zeaxanthin treats or prevents antimalarial retinal toxicity in humans. Supplements are not a substitute for stopping the offending medicine under medical guidance, and you should discuss any supplement with your doctors.

Get notified when new evidence is published on Toxic maculopathy due to antimalarial drugs.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Unmet needs and future perspectives in hydroxychloroquine retinopathy.

    Yusuf IH, Charbel Issa P, Ahn SJ

    Frontiers in medicine 2023; (10()):1196815 doi:10.3389/fmed.2023.1196815.

    PMID: 37359010
  2. 2

    Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

    Marmor MF, Kellner U, Lai TY, et al.

    Ophthalmology 2016; (123(6)):1386-94.

    PMID: 26992838
  3. 3

    Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.

    Snow Z, Seely K, Barrett S, et al.

    Current ophthalmology reports 2024; (12(3)):38-48 doi:10.1007/s40135-024-00321-6.

    PMID: 39371107
  4. 4

    Risk of flare in patients with SLE in remission after hydroxychloroquine or chloroquine withdrawal.

    Trefond L, Mathian A, Lhote R, et al.

    Joint bone spine 2024; (91(6)):105756 doi:10.1016/j.jbspin.2024.105756.

    PMID: 38964624
  5. 5

    EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

    Fanouriakis A, Kostopoulou M, Andersen J, et al.

    Annals of the rheumatic diseases 2024; (83(1)):15-29 doi:10.1136/ard-2023-224762.

    PMID: 37827694
  6. 6

    Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

    Stohl W, Schwarting A, Okada M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(5)):1016-1027 doi:10.1002/art.40049.

    PMID: 28118533
  7. 7

    Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

    Furie R, Rovin BH, Houssiau F, et al.

    The New England journal of medicine 2020; (383(12)):1117-1128 doi:10.1056/NEJMoa2001180.

    PMID: 32937045
  8. 8

    Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumtic drugs.

    Walker UA

    Seminars in hematology 2016; (53 Suppl 1()):S58-60.

    PMID: 27312168
  9. 9

    Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report.

    Omran NE, Noorwali AA

    International journal of general medicine 2018; (11()):151-154 doi:10.2147/IJGM.S154835.

    PMID: 29692623
  10. 10

    Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.

    Bays AM, Gardner G

    The Medical clinics of North America 2016; (100(4)):719-31.

    PMID: 27235612
  11. 11

    The Relationship of Hydroxychloroquine Retinopathy Progression to Stage at Cessation of Therapy.

    Browning DJ, Koonce DR, Mentreddy A, Punjabi O

    American journal of ophthalmology 2025; (277()):335-348 doi:10.1016/j.ajo.2025.05.030.

    PMID: 40447243
  12. 12

    Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation.

    Gutowski E, Modi Y, Velez AG, et al.

    Research square 2026; doi:10.21203/rs.3.rs-10488914/v1.

    PMID: 42687909
  13. 13

    SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity.

    Pham BH, Marmor MF

    Retina (Philadelphia, Pa.) 2019; (39(3)):492-501 doi:10.1097/IAE.0000000000002408.

    PMID: 30550532
  14. 14

    LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.

    Allahdina AM, Chen KG, Alvarez JA, et al.

    Retina (Philadelphia, Pa.) 2019; (39(3)):473-484 doi:10.1097/IAE.0000000000002437.

    PMID: 30741731
  15. 15

    Delayed progression of bull's eye maculopathy.

    Jain S, Jain NG

    BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-220598.

    PMID: 28596207
  16. 16

    Zeaxanthin Mitigates Hydroxychloroquine-Induced Retinal Toxicity and Metabolic Reprogramming in ARPE-19 Cells.

    Altıparmak MBA, Yıldırım EM, Kaplan O, et al.

    Journal of biochemical and molecular toxicology 2026; (40(7)):e71015 doi:10.1002/jbt.71015.

    PMID: 42421451

This page explains treatment changes and eye monitoring after antimalarial retinal toxicity for informational purposes only and does not constitute medical advice. Do not stop hydroxychloroquine or chloroquine without coordinating with your prescribing clinician and eye doctor.